Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis

American Journal of Gastroenterology

Volumn 108, Issue 9, 2013, Pages 1417-1425

  Singh, Siddharth ^a   Loftus, Edward V ^a   Talwalkar, Jayant A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BALSALAZIDE; CYCLOSPORIN; MESALAZINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SALAZOSULFAPYRIDINE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CANCER RISK; CLOSTRIDIUM INFECTION; COLON RESECTION; COLORECTAL CANCER; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DISEASE COURSE; DYSPLASIA; ENTERITIS; GRAFT REJECTION; HUMAN; ILEITIS; ILEOANAL ANASTOMOSIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKOPENIA; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MALIGNANT TRANSFORMATION; OUTCOME ASSESSMENT; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURVIVAL; SYSTEMATIC REVIEW;

CHOLANGITIS, SCLEROSING; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER TRANSPLANTATION; RISK FACTORS; SURVIVAL RATE;

EID: 84883743110     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.163     Document Type: Review

References (87)

1. Bambha K , Kim WR , Talwalkar J et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003 ; 125 : 1364-9.
2. Broome U , Olsson R , Loof L et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996 ; 38 : 610-5.
3. Farrant JM , Hayllar KM , Wilkinson ML et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991 ; 100 : 1710-7.
4. Kingham JG , Kochar N , Gravenor MB. Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004 ; 126 : 1929-30.
5. Ponsioen CY , Vrouenraets SM , Prawirodirdjo W et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002 ; 51 : 562-6.
6. Tischendorf JJ , Hecker H , Kruger M et al. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: A single center study. Am J Gastroenterol 2007 ; 102 : 107-14.
7. Wiesner RH , Grambsch PM , Dickson ER et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989 ; 10 : 430-6.
8. Kashyap R , Safadjou S , Chen R et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases-an analysis of the UNOS database. J Gastrointest Surg 2010 ; 14 : 1362-9.
9. Boonstra K , Beuers U , Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012 ; 56 : 1181-8.
10. Loftus Jr EV , Harewood GC , Loftus CG et al. PSC-IBD: a unique form of Inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 2005 ; 54 : 91-6.
11. Boonstra K , van Erpecum KJ , van Nieuwkerk KM et al. Primary sclerosing cholangitis is associated with a distinct phenotype of Inflammatory bowel disease. Infl amm Bowel Dis 2012.
12. Joo M , Abreu-e-Lima P , Farraye F et al. Pathologic features of ulcerative colitis in patients with primary sclerosing cholangitis: a case-control study. Am J Surg Pathol 2009 ; 33 : 854-62.
13. O ' Toole A , Alakkari A , Keegan D et al. Primary sclerosing cholangitis and disease distribution in Inflammatory bowel disease. Clin Gastroenterol Hepatol 2012 ; 10 : 439-41.
14. Sokol H , Cosnes J , Chazouilleres O et al. Disease activity and cancer risk in Inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 2008 ; 14 : 3497-503.
15. Jorgensen KK , Grzyb K , Lundin KEA et al. Inflammatory bowel disease in patients with primary sclerosing cholangitis: Clinical characterization in liver transplanted and nontransplanted patients. Infl amm Bowel Dis 2012 ; 18 : 536-45.
16. Soetikno RM , Lin OS , Heidenreich PA et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002 ; 56 : 48-54.
17. Befeler AS , Lissoos TW , Schiano TD et al. Clinical course and management of Inflammatory bowel disease after liver transplantation. Transplantation 1998 ; 65 : 393-6.
18. Cholongitas E , Papatheodoridis GV , Zappoli P et al. Combined HLA-DR and-DQ disparity is associated with a stable course of ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Liver Transpl 2007 ; 13 : 552-7.
19. Dvorchik I , Subotin M , Demetris AJ et al. Effect of liver transplantation on Inflammatory bowel disease in patients with primary sclerosing cholangitis. Hepatology 2002 ; 35 : 380-4.
20. Haagsma EB , Van Den Berg AP , Kleibeuker JH et al. Inflammatory bowel disease after liver transplantation: the Effect of diff erent immunosuppressive regimens. Aliment Pharmacol Ther 2003 ; 18 : 33-44.
21. Riley TR , Schoen RE , Lee RG et al. A case series of transplant recipients who despite immunosuppression developed Inflammatory bowel disease. Am J Gastroenterol 1997 ; 92 : 279-82.
22. Worns MA , Lohse AW , Neurath MF et al. Five cases of de novo Inflammatory bowel disease after orthotopic liver transplantation. Am J Gastroenterol 2006 ; 101 : 1931-7.
23. Cho CS , Dayton MT , Th ompson JS et al. Proctocolectomy-ileal pouch-anal anastomosis for ulcerative colitis after liver transplantation for primary sclerosing cholangitis: a multi-institutional analysis. J Gastrointest Surg 2008 ; 12 : 1221-6.
24. Freeman K , Shao Z , Remzi FH et al. Impact of orthotopic liver transplant for primary sclerosing cholangitis on chronic antibiotic refractory pouchitis. Clin Gastroenterol Hepatol 2008 ; 6 : 62-8.
25. Mathis KL , Dozois EJ , Larson DW et al. Ileal pouch-anal anastomosis and liver transplantation for ulcerative colitis complicated by primary sclerosing cholangitis. Br J Surg 2008 ; 95 : 882-6.
26. Watt KD , Pedersen RA , Kremers WK et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010 ; 10 : 1420-7.
27. Watt KD , Pedersen RA , Kremers WK et al. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009 ; 137 : 2010-7.
28. Fabia R , Levy MF , Testa G et al. Colon carcinoma in patients undergoing liver transplantation. Am J Surg 1998 ; 176 : 265-9.
29. Haagsma EB , Hagens VE , Schaapveld M et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol 2001 ; 34 : 84-91.
30. Hanouneh IA , Macaron C , Lopez R et al. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis. Infl amm Bowel Dis 2012 ; 18 : 269-74.
31. Gavaler JS , Delemos B , Belle SH et al. Ulcerative colitis disease activity as subjectively assessed by patient-completed questionnaires following orthotopic liver transplantation for sclerosing cholangitis. Dig Dis Sci 1991 ; 36 : 321-8.
32. MacLean AR , Lilly L , Cohen Z et al. Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis. Dis Colon Rectum 2003 ; 46 : 1124-8.
33. Moncrief KJ , Savu A , Ma MM et al. The natural history of Inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation-A single-centre experience. Can J Gastroenterol 2010 ; 24 : 40-6.
34. Navaneethan U , Choudhary M , Venkatesh PG et al. The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. Aliment Pharmacol Ther 2012 ; doi: 10.1111/j.1365-2036.2012.05067.x.
35. Papatheodoridis GV , Hamilton M , Mistry PK et al. Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut 1998 ; 43 : 639-44.
36. Saldeen K , Friman S , Olausson M et al. Follow-up after liver transplantation for primary sclerosing cholangitis: Effects on survival, quality of life, and colitis. Scand J Gastroenterol 1999 ; 34 : 535-40.
37. Shaked A , Colonna JO , Goldstein L et al. The interrelation between sclerosing cholangitis and ulcerative colitis in patients undergoing liver transplantation. Ann Surg 1992 ; 215 : 598-603 ; discussion 604-5.
38. Stephens J , Goldstein R , Crippin J et al. Effects of orthotopic liver transplantation and immunosuppression on Inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 1993 ; 25 : 1122-3.
39. van de Vrie W , de Man RA , van Buuren HR et al. Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2003 ; 15 : 657-63.
40. Verdonk RC , Dijkstra G , Haagsma EB et al. Inflammatory bowel disease after liver transplantation: risk factors for recurrence and de novo disease. Am J Transplant 2006 ; 6 : 1422-9.
41. J ø rgensen KK LL , Cvancarova M , Schrumpf E et al. Clinical course of Inflammatory bowel disease in liver transplanted PSC patients:a Nordic Multicenter Study. In: Digestive Diseases Week; 2012; San Diego Gastroenterology 2012 p. S7-8.
42. Joshi D , Bjarnason I , Belgaumkar A et al. The impact of Inflammatory bowel disease post-liver transplantation for primary sclerosing cholangitis. Liver Int 2011.
43. Miki C , Harrison JD , Gunson BK et al. Inflammatory bowel disease in primary sclerosing cholangitis: an analysis of patients undergoing liver transplantation. Br J Surg 1995 ; 82 : 1114-7.
44. Marelli L , Xirouchakis E , Kalambokis G et al. Does the severity of primary sclerosing cholangitis infl uence the clinical course of associated ulcerative colitis? Gut 2011 ; 60 : 1224-8.
45. Navaneethan U , Venkatesh PG , Mukewar S et al. Progressive primary sclerosing cholangitis requiring liver transplantation is associated with reduced need for colectomy in patients with ulcerative colitis. Clin Gastroenterol Hepatol 2012 ; 10 : 540-6.
46. Ho GT , Seddon AJ , Therapondos G et al. The clinical course of ulcerative colitis after orthotopic liver transplantation for primary sclerosing cholangitis: further appraisal of immunosuppression post transplantation. Eur J Gastroenterol Hepatol 2005 ; 17 : 1379-85.
47. Gabe SM , Bjarnason I , Tolou-Ghamari Z et al. The Effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. Gastroenterology 1998 ; 115 : 67-74.
48. Papatheodoridis GV , Hamilton M , Rolles K et al. Liver transplantation and Inflammatory bowel disease. J Hepatol 1998 ; 28 : 1070-6.
49. Niessner M , Volk BA. Phenotypic and immunoregulatory analysis of intestinal T-cells in patients with Inflammatory bowel disease: evaluation of an in vitro model. Eur J Clin Invest 1995 ; 25 : 155-64.
50. Senju M , Hulstaert F , Lowder J et al. Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease. Gut 1991 ; 32 : 779-83.
51. Ramji A , Owen DA , Erb SR et al. Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance? Dig Dis Sci 2002 ; 47 : 522-7.
52. Verdonk RC , Haagsma EB , Van Den Berg AP et al. Inflammatory bowel disease after liver transplantation: a role for cytomegalovirus infection. Scand J Gastroenterol 2006 ; 41 : 205-11.
53. Rowley S , Candinas D , Mayer AD et al. Restorative proctocolectomy and pouch anal anastomosis for ulcerative colitis following orthotopic liver transplantation. Gut 1995 ; 37 : 845-7.
54. Zins BJ , Sandborn WJ , Penna CR et al. Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol 1995 ; 90 : 2177-81.
55. Albright JB , Bonatti H , Stauff er J et al. Colorectal and anal neoplasms following liver transplantation. Colorectal Dis 2010 ; 12 : 657-66.
56. Bleday R , Lee E , Jessurun J et al. Increased risk of early colorectal neoplasms after hepatic transplant in patients with Inflammatory bowel disease. Dis Colon Rectum 1993 ; 36 : 908-12.
57. Higashi H , Yanaga K , Marsh JW et al. Development of colon cancer after liver transplantation for primary sclerosing cholangitis associated with ulcerative colitis. Hepatology 1990 ; 11 : 477-80.
58. Jonas S , Rayes N , Neumann U et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997 ; 80 : 1141-50.
59. Johnson EE , Leverson GE , Pirsch JD et al. A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening. J Gastrointest Surg 2007 ; 11 : 272-9.
60. Jorgensen KK , Lindstrom L , Cvancarova M et al. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study. Scand J Gastroenterol 2012 ; 47 : 1021-9.
61. Kelly DM , Emre S , Guy SR et al. Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors. Cancer 1998 ; 83 : 1237-43.
62. Knechtle SJ , D ' Alessandro AM , Harms BA et al. Relationships between sclerosing cholangitis, Inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery 1995 ; 118 : 615-9 ; discussion 619-20.
63. Loftus Jr EV , Aguilar HI , Sandborn WJ et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. Hepatology 1998 ; 27 : 685-90.
64. Narumi S , Roberts JP , Emond JC et al. Liver transplantation for sclerosing cholangitis. Hepatology 1995 ; 22 : 451-7.
65. Sint Nicolaas J , Tjon AS , Metselaar HJ et al. Colorectal cancer in post-liver transplant recipients. Dis Colon Rectum 2010 ; 53 : 817-21.
66. Vera A , Gunson BK , Ussatoff V et al. Colorectal cancer in patients with Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 2003 ; 75 : 1983-8.
67. Goss JA , Shackleton CR , Farmer DG et al. Orthotopic liver transplantation for primary sclerosing cholangitis. A 12-year single center experience. Ann Surg 1997 ; 225 : 472-481; discussion 481-3.
68. Jain AB , Yee LD , Nalesnik MA et al. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. Transplantation 1998 ; 66 : 1193-200.
69. Koornstra JJ , Wesseling J , de Jong AE et al. Increased risk of colorectal neoplasia in asymptomatic liver-transplant recipients. Gut 2007 ; 56 : 892-3.
70. Oo YH , Gunson BK , Lancashire RJ et al. Incidence of cancers following orthotopic liver transplantation in a single center: comparison with national cancer incidence rates for England and Wales. Transplantation 2005 ; 80 : 759-64.
71. Sint Nicolaas J , de Jonge V , Steyerberg EW et al. Risk of colorectal carcinoma in post-liver transplant patients: a systematic review and meta-analysis. Am J Transplant 2010 ; 10 : 868-76.
72. Nishihori T , Strazzabosco M , Saif MW. Incidence and management of colorectal cancer in liver transplant recipients. Clin Colorectal Cancer 2008 ; 7 : 260-6.
73. Fosby B , Karlsen TH , Melum E. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis. World J Gastroenterol 2012 ; 18 : 1-15.
74. Egawa H , Taira K , Teramukai S et al. Risk factors for recurrence of primary sclerosing cholangitis after living donor liver transplantation: a single center experience. Dig Dis Sci 2009 ; 54 : 1347-54.
75. Alabraba E , Nightingale P , Gunson B et al. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allograft s. Liver Transpl 2009 ; 15 : 330-40.
76. Rowe IA , Webb K , Gunson BK et al. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transpl Int 2008 ; 21 : 459-65.
77. Cholongitas E , Shusang V , Papatheodoridis GV et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008 ; 14 : 138-43.
78. Grant AJ , Lalor PF , Salmi M et al. Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of Inflammatory bowel disease. Lancet 2002 ; 359 : 150-7.
79. Alexander J , Lord JD , Yeh MM et al. Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2008 ; 14 : 245-51.
80. Campsen J , Zimmerman MA , Trotter JF et al. Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl 2008 ; 14 : 181-5.
81. Graziadei IW , Wiesner RH , Marotta PJ et al. Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999 ; 30 : 1121-7.
82. Ginsburg PM , Th uluvath PJ. Diarrhea in liver transplant recipients: etiology and management. Liver Transpl 2005 ; 11 : 881-90.
83. Lowry PW , Franklin CL , Weaver AL et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001 ; 49 : 656-64.
84. Mohabbat AB , Sandborn WJ , Loftus Jr EV et al. Anti-tumour necrosis factor treatment of Inflammatory bowel disease in liver transplant recipients. Aliment Pharmacol Ther 2012 ; 36 : 569-74.
85. Sandhu A , Alameel T , Dale CH et al. The safety and effi cacy of antitumour necrosis factor-alpha therapy for Inflammatory bowel disease in patients post liver transplantation: a case series. Aliment Pharmacol Ther 2012 ; 36 : 159-65.
86. Bosso MC , Marchesa PE , Ricchiuti A et al. Proctocolectomy for ulcerative colitis after liver transplantation for primary sclerosing cholangitis. Transplant Proc 2009 ; 41 : 1390-2.
87. Kornbluth A , Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010 ; 105 : 501-23 ; quiz 524.